• Guoming Chen, Jinlong Zhao, Tengyu Chen, Zhaoping Zhang, Chuyao Huang, Zhirui Xu, and Hua Xu.
• Guangzhou University of Chinese Medicine.
• Medicine (Baltimore). 2018 Nov 1; 97 (45): e13039e13039.

BackgroundUrticaria is a common skin disease that has a high impact on a patient's daily life. Xiaofeng powder (XFP) is one of the most commonly used Chinese herbal formula in China for urticaria. However, due to the lack of systematic evaluations, its clinical efficacy remains controversial. This meta-analysis was performed to evaluate the effect and safety of XFP for urticaria.MethodsSeven databases, including Cochrane Central Register of Controlled Trials, PubMed, Embase, the Chinese National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP), the Chinese Biomedical Literature Database (CBM), and the Wanfang Database. The period will be from their inception to September 2018. Randomized controlled trials of XFS used separately against conventional Western medicine therapy in patients with urticarial were included. After the methodologic quality was assessed and the valid data were extracted, RevMan 5.3 software was used for the final meta-analysis.ResultsThe results will provide evidence regarding the efficacy and safety of XFP in treating urticaria.ConclusionThe conclusion of our systematic review will provide evidence to judge whether XFP is an effective intervention for patient with urticaria. This systematic review will be disseminated in peer-reviewed publications. The results of the study will provide evidence concerning the efficacy and safety of Xiaofeng Powder (xiao feng san) in treating urticaria.Prospero Registration NumberPROSPERO CRD 42018087260.

13 keywords...

hide…